Extracellular matrix proteins and tumor angiogenesis

Journal of Oncology

Volumn , Issue , 2010, Pages

  Petrik, J ^a   Campbell, N E ^a   Kellenberger, L ^a   Greenaway, J ^b   Moorehead, R A ^a   Linnerth Petrik, N M ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 2; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; PROTEINASE; SCLEROPROTEIN; STRUCTURAL PROTEIN; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CARCINOGENESIS; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; STROMA; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 77955352820     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/586905     Document Type: Review

References (176)

1. Radisky D., Hagios C., Bissell M. J., Tumors are unique organs defined by abnormal signaling and context Seminars in Cancer Biology 2001 11 2 87 95
2. Brekken C., Bruland O. S., de Lange Davies C., Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase Anticancer Research 2000 20 5 3503 3512
3. Fukumura D., Yuan F., Monsky W. L., Chen Y., Jain R. K., Effect of host microenvironment on the microcirculation of human colon adenocarcinoma American Journal of Pathology 1997 151 3 679 688
4. Killion J. J., Radinsky R., Fidler I. J., Orthotopic models are necessary to predict therapy of transplantable tumors in mice Cancer and Metastasis Reviews 1998 17 3 279 284
5. Greenaway J., Moorehead R., Shaw P., Petrik J., Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer Gynecologic Oncology 2008 108 2 385 394
6. Wernert N., The multiple roles of tumour stroma Virchows Archiv 1997 430 6 433 443
7. Folkman J., Tumor angiogenesis: therapeutic implications New England Journal of Medicine 1971 285 21 1182 1186
8. Folkman J., Klagsbrun M., Angiogenic factors Science 1987 235 4787 442 447
9. Folkman J., Watson K., Ingber D., Hanahan D., Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 1989 339 6219 58 61
10. Carmeliet P., Angiogenesis in health and disease Nature Medicine 2003 9 6 653 660
11. Ferrara N., Houck K., Jakeman L., Leung D. W., Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocrine Reviews 1992 13 1 18 32
12. Galzie Z., Kinsella A. R., Smith J. A., Fibroblast growth factors and their receptors Biochemistry and Cell Biology 1997 75 6 669 685
13. Compagni A., Wilgenbus P., Impagnatiello M.-A., Cotten M., Christofori G., Fibroblast growth factors are required for efficient tumor angiogenesis Cancer Research 2000 60 24 7163 7169
14. Gerwins P., Skldenberg E., Claesson-Welsh L., Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis Critical Reviews in Oncology/Hematology 2000 34 3 185 194
15. Rabbani S. A., Metalloproteases and urokinase in angiogenesis and tumor progression In Vivo 1998 12 1 135 142
16. Geisler J. P., Miller G. A., Broshears J. R., Manahan K. J., Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma Journal of Surgical Oncology 2007 96 6 514 517
17. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Susan Harvey V., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 219 4587 983 985
18. De Cecco L., Marchionni L., Gariboldi M., Reid J. F., Lagonigro M. S., Caramuta S., Ferrario C., Bussani E., Mezzanzanica D., Turatti F., Delia D., Daidone M. G., Oggionni M., Bertuletti N., Ditto A., Raspagliesi F., Pilotti S., Pierotti M. A., Canevari S., Schneider C., Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 Oncogene 2004 23 49 8171 8183
19. Salgado R., Benoy I., Vermeulen P., van Dam P., van Marck E., Dirix L., Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer Angiogenesis 2004 7 1 29 32
20. Di Blasio A. M., Carniti C., Vigano P., Vignali M., Basic fibroblast growth factor and ovarian cancer Journal of Steroid Biochemistry and Molecular Biology 1995 53 16 375 379
21. Whitworth M. K., Backen A. C., Clamp A. R., Wilson G., Mc Vey R., Friedl A., Rapraeger A. C., David G., McGown A., Slade R. J., Gallagher J. T., Jayson G. C., Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium Clinical Cancer Research 2005 11 12 4282 4288
22. Klagsbrun M., D'Amore P. A., Regulators of angiogenesis Annual Review of Physiology 1991 53 217 239
23. Sottile J., Regulation of angiogenesis by extracellular matrix Biochimica et Biophysica Acta 2004 1654 1 13 22
24. Rouet V., Hamma-Kourbali Y., Petit E., Panagopoulou P., Katsoris P., Barritault D., Caruelle J.-P., Courty J., A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis Journal of Biological Chemistry 2005 280 38 32792 32800
25. Yip G. W., Smollich M., Gtte M., Therapeutic value of glycosaminoglycans in cancer Molecular Cancer Therapeutics 2006 5 9 2139 2148
26. Gth M. I., Hubina E., Raptis S., Nagy G. M., Tth B. E., Physiological and pathological angiogenesis in the endocrine system Microscopy Research and Technique 2003 60 1 98 106
27. Iozzo R. V., San Antonio J. D., Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena Journal of Clinical Investigation 2001 108 3 349 355
28. Sasisekharan R., Moses M. A., Nugent M. A., Cooney C. L., Langer R., Heparinase inhibits neovascularization Proceedings of the National Academy of Sciences of the United States of America 1994 91 4 1524 1528
29. Walker A., Turnbull J. E., Gallagher J. T., Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor Journal of Biological Chemistry 1994 269 2 931 935
30. Karumanchi S. A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J.-I., Venkataraman G., Shriver Z., Keiser N., Kalluri R., Zeng H., Mukhopadhyay D., Chen R. L., Lander A. D., Hagihara K., Yamaguchi Y., Sasisekharan R., Cantley L., Sukhatme V. P., Cell surface glypicans are low-affinity endostatin receptors Molecular Cell 2001 7 4 811 822
31. Mundel T. M., Kalluri R., Type IV collagen-derived angiogenesis inhibitors Microvascular Research 2007 74 2-3 85 89
32. Pepper M. S., Extracellular proteolysis and angiogenesis Thrombosis and Haemostasis 2001 86 1 346 355
33. Saksela O., Rifkin D. B., Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity Journal of Cell Biology 1990 110 3 767 775
34. Kaur B., Brat D. J., Devi N. S., Van Meir E. G., Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor Oncogene 2005 24 22 3632 3642
35. Hanford H. A., Wong C. A., Kassan H., Cundiff D. L., Chandel N., Underwood S., Mitchell C. A., Soff G. A., Angiostatin4.5-mediated apoptosis of vascular endothelial cells Cancer Research 2003 63 14 4275 4280 (Pubitemid 36917957)
36. Folkman J., Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin Science's STKE 2006 2006 354, article pe35
37. Yang J. T., Rayburn H., Hynes R. O., Embryonic mesodermal defects in 5 integrin-deficient mice Development 1993 119 4 1093 1105
38. Goh K. L., Yang J. T., Hynes R. O., Mesodermal defects and cranial neural crest apoptosis in 5 integrin-null embryos Development 1997 124 21 4309 4319
39. Francis S. E., Goh K. L., Hodivala-Dilke K., Bader B. L., Stark M., Davidson D., Hynes R. O., Central roles of 5 1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 6 927 933
40. Marcinkiewicz C., Weinreb P. H., Calvete J. J., Kisiel D. G., Mousa S. A., Tuszynski G. P., Lobb R. R., Obtustatin: a potent selective inhibitor of 1 1 integrin in vitro and angiogenesis in vivo Cancer Research 2003 63 9 2020 2023
41. Tashiro K., Sephel G. C., Weeks B., Sasaki M., Martin G. R., Kleinman H. K., Yamada Y., A synthetic peptide containing the IKVAV sequence from the A chain of laminin mediates cell attachment, migration, and neurite outgrowth Journal of Biological Chemistry 1989 264 27 16174 16182
42. Kibbey M. C., Grant D. S., Kleinman H. K., Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo Matrigel model Journal of the National Cancer Institute 1992 84 21 1633 1638
43. Malinda K. M., Nomizu M., Chung M., Delgado M., Kuratomi Y., Yamada Y., Kleinman H. K., Ponce M. L., Identification of laminin 1 and 1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting FASEB Journal 1999 13 1 53 62
44. Mettouchi A., Klein S., Guo W., Lopez-Lago M., Lemichez E., Westwick J. K., Giancotti F. G., Integrin-specific activation of Rac controls progression through the G1 phase of the cell cycle Molecular Cell 2001 8 1 115 127
45. Pepper M. S., Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 7 1104 1117
46. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S., Reduced angiogenesis and tumor progression in gelatinase A-deficient mice Cancer Research 1998 58 5 1048 1051
47. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., Harper J., Tamvakopoulos G., Moses M. A., Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model Proceedings of the National Academy of Sciences of the United States of America 2000 97 8 3884 3889
48. Zhang A., Meng L., Wang Q., Xi L., Chen G., Wang S., Zhou J., Lu Y., Ma D., Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2 Oncology Reports 2006 15 4 831 836
49. Lee S., Jilan S. M., Nikolova G. V., Carpizo D., Luisa Iruela-Arispe M., Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors Journal of Cell Biology 2005 169 4 681 691
50. Hollborn M., Stathopoulos C., Steffen A., Wiedemann P., Kohen L., Bringmann A., Positive feedback regulation between MMP-9 and VEGF in human RPE cells Investigative Ophthalmology and Visual Science 2007 48 9 4360 4367
51. Hawinkels L. J. A. C., Zuidwijk K., Verspaget H. W., de Jonge-Muller E. S. M., Duijn W. V., Ferreira V., Fontijn R. D., David G., Hommes D. W., Lamers C. B. H. W., Sier C. F. M., VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis European Journal of Cancer 2008 44 13 1904 1913
52. Onguchi T., Han K. Y., Chang J.-H., Azar D. T., Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization American Journal of Pathology 2009 174 4 1564 1571
53. Sounni N. E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E. W., Foidart J. M., Noel A., MTI-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression FASEB Journal 2002 16 6 555 564
54. Deryugina E. I., Soroceanu L., Strongin A. Y., Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis Cancer Research 2002 62 2 580 588
55. Rodrguez-Manzaneque J. C., Lane T. F., Ortega M. A., Hynes R. O., Lawler J., Iruela-Arispe M. L., Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor Proceedings of the National Academy of Sciences of the United States of America 2001 98 22 12485 12490
56. Trimboli A. J., Cantemir-Stone C. Z., Li F., Wallace J. A., Merchant A., Creasap N., Thompson J. C., Caserta E., Wang H., Chong J.-L., Naidu S., Wei G., Sharma S. M., Stephens J. A., Fernandez S. A., Gurcan M. N., Weinstein M. B., Barsky S. H., Yee L., Rosol T. J., Stromberg P. C., Robinson M. L., Pepin F., Hallett M., Park M., Ostrowski M. C., Leone G., Pten in stromal fibroblasts suppresses mammary epithelial tumours Nature 2009 461 7267 1084 1091
57. Kalluri R., Basement membranes: structure, assembly and role in tumour angiogenesis Nature Reviews Cancer 2003 3 6 422 433
58. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R. A., Moses M., Lane W. S., Cao Y., Helene Sage E., Folkman J., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 1994 79 2 315 328
59. Ikenaka Y., Yoshiji H., Kuriyama S., Yosh J. II, Noguchi R., Tsujinoue H., Yanase K., Namisaki T., Imazu H., Masaki T., Fukui H., Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model International Journal of Cancer 2003 105 3 340 346 (Pubitemid 36570046)
60. Seo D.-W., Li H., Guedez L., Wingfield P. T., Diaz T., Salloum R., Wei B.-Y., Stetler-Stevenson W. G., TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism Cell 2003 114 2 171 180
61. Valente P., Fassina G., Melchiori A., Masiello L., Cilli M., Vacca A., Onisto M., Santi L., Stetler-Stevenson W. G., Albini A., TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis International Journal of Cancer 1998 75 2 246 253
62. Feldman A. L., Stetler-Stevenson W. G., Costouros N. G., Knezevic V., Baibakov G., Alexander H. R. Jr., Lorang D., Hewitt S. M., Seo D.-W., Miller M. S., O'Connor S., Libutti S. K., Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism Cancer Research 2004 64 13 4481 4486
63. Hajitou A., Sounni N.-E., Devy L., Grignet-Debrus C., Lewalle J.-M., Li H., Deroanne C. F., Lu H., Colige A., Nusgens B. V., Frankenne F., Maron A., Yeh P., Perricaudet M., Chang Y., Soria C., Calberg-Bacq C.-M., Foidart J.-M., Nol A., Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis Cancer Research 2001 61 8 3450 3457
64. Seo D.-W., Kim S. H., Eom S.-H., Yoon H. J., Cho Y.-R., Kim P.-H., Kim Y. K., Han J.-W., Diaz T., Wei B.-Y., Stetler-Stevenson W. G., TIMP-2 disrupts FGF-2-induced downstream signaling pathways Microvascular Research 2008 76 3 145 151
65. Spurbeck W. W., Ng C. Y. C., Strom T. S., Vanin E. F., Davidoff A. M., Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model Blood 2002 100 9 3361 3368
66. Kang K.-H., Park S.-Y., Rho S. B., Lee J.-H., Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis Cardiovascular Research 2008 79 1 150 160
67. Chetty C., Lakka S. S., Bhoopathi P., Kunigal S., Geiss R., Rao J. S., Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer Cancer Research 2008 68 12 4736 4745
68. Cruz-Muoz W., Kim I., Khokha R., TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis Oncogene 2006 25 4 650 655
69. Corcoran M. L., Stetler-Stevenson W. G., Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism Journal of Biological Chemistry 1995 270 22 13453 13459
70. Hoegy S. E., Oh H.-R., Corcoran M. L., Stetler-Stevenson W. G., Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition Journal of Biological Chemistry 2001 276 5 3203 3214
71. Oh J., Seo B.-W., Diaz T., Wei B., Ward Y., Ray J. M., Morioka Y., Shi S., Kitayama H., Takahashi C., Noda M., Sletler-Stevenson W. G., Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK Cancer Research 2004 64 24 9062 9069
72. Fernndez C. A., Butterfield C., Jackson G., Moses M. A., Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor Journal of Biological Chemistry 2003 278 42 40989 40995
73. Dunn J. R., Reed J. E., du Plessis D. G., Shaw E. J., Reeves P., Gee A. L., Warnke P., Walker C., Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours British Journal of Cancer 2006 94 8 1186 1193
74. Goz P., Goz M., Baldys A., Hoffman S., ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis Biochemical and Biophysical Research Communications 2009 380 1 33 38
75. Sharghi-Namini S., Fan H., Sulochana K. N., Potturi P., Xiang W., Chong Y.-S., Wang Z., Yang H., Ge R., The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor Biochemical and Biophysical Research Communications 2008 371 2 215 219
76. Vzquez F., Hastings G., Ortega M.-A., Lane T. F., Oikemus S., Lombardo M., Iruela-Arispe M. L., METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity Journal of Biological Chemistry 1999 274 33 23349 23357
77. Luque A., Carpizo D. R., Iruela-Arispe M. L., ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165 Journal of Biological Chemistry 2003 278 26 23656 23665
78. Podhajcer O. L., Benedetti L. G., Girotti M. R., Prada F., Salvatierra E., Llera A. S., The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host Cancer and Metastasis Reviews 2008 27 4 691 705
79. Chlenski A., Liu S., Guerrero L. J., Yang Q., Tian Y., Salwen H. R., Zage P., Cohn S. L., SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix International Journal of Cancer 2006 118 2 310 316
80. Yunker C. K., Golembieski W., Lemke N., Schultz C. R., Cazacu S., Brodie C., Rempel S. A., SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion International Journal of Cancer 2008 122 12 2735 2743
81. Chlenski A., Guerrero L. J., Yang Q., Tian Y., Peddinti R., Salwen H. R., Cohn S. L., SPARC enhances tumor stroma formation and prevents fibroblast activation Oncogene 2007 26 31 4513 4522
82. Kupprion C., Motamed K., Sage E. H., SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells Journal of Biological Chemistry 1998 273 45 29635 29640
83. Nyberg P., Xie L., Kalluri R., Endogenous inhibitors of angiogenesis Cancer Research 2005 65 10 3967 3979
84. Folkman J., Endogenous angiogenesis inhibitors APMIS 2004 112 7-8 496 507
85. Good D. J., Polverini P. J., Rastinejad F., Le Beau M. M., Lemons R. S., Frazier W. A., Bouck N. P., A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin Proceedings of the National Academy of Sciences of the United States of America 1990 87 17 6624 6628
86. Schmierer B., Hill C. S.
87. David L., Feige J.-J., Bailly S., Emerging role of bone morphogenetic proteins in angiogenesis Cytokine and Growth Factor Reviews 2009 20 3 203 212
88. Deckers M. M. L., van Bezooijen R. L., van Geertje Horst D. E. R., Hoogendam J., van Chris Bent D. E. R., Papapoulos S. E., Lwik C. W. G. M., Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A Endocrinology 2002 143 4 1545 1553
89. Rothhammer T., Bataille F., Spruss T., Eissner G., Bosserhoff A.-K., Functional implication of BMP4 expression on angiogenesis in malignant melanoma Oncogene 2007 26 28 4158 4170
90. Mathura J. R. Jr., Jafari N., Chang J. T., Hackett S. F., Wahlin K. J., Della N. G., Okamoto N., Zack D. J., Campochiaro P. A., Bone morphogenetic proteins-2 and-4: negative growth regulators in adult retinal pigmented epithelium Investigative Ophthalmology and Visual Science 2000 41 2 592 600
91. Kane R., Godson C., O'Brien C., Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis Molecular Vision 2008 14 1138 1148
92. ten Dijke P., Arthur H. M.
93. Morrissey C., Brown L. G., Pitts T. E. M., Vessella R. L., Corey E., Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment Neoplasia 2010 12 2 192 205
94. Langenfeld E. M., Kong Y., Langenfeld J., Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5 Oncogene 2006 25 5 685 692
95. Bailey J. M., Singh P. K., Hollingsworth M. A., Cancer metastasis facilitated by developmental pathways: sonic hedgehog, notch, and bone morphogenic proteins Journal of Cellular Biochemistry 2007 102 4 829 839
96. Takiguchi T., Kobayashi M., Suzuki R., Yamaguchi A., Isatsu K., Nishihara T., Nagumo M., Hasegawa K., Recombinant human bone morphogenetic protein-2 stimulates osteoblast differentiation and suppresses matrix metalloproteinase-1 production in human bone cells isolated from mandibulae Journal of Periodontal Research 1998 33 8 476 485
97. Kumagai T., Shimizu T., Takeda K., Bone morphogenetic protein-2 suppresses invasiveness of TSU-Pr1 cells with the inhibition of MMP-9 secretion Anticancer Research 2006 26 1 293 298
98. Otto T. C., Bowers R. R., Lane M. D.
99. Shepherd T. G., Mujoomdar M. L., Nachtigal M. W., Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion Journal of Ovarian Research 2010 3 1, article 5
100. Baenziger N. L., Brodie G. N., Majerus P. W., A thrombin-sensitive protein of human platelet membranes Proceedings of the National Academy of Sciences of the United States of America 1971 68 1 240 243
101. Baenziger N. L., Brodie G. N., Majerus P. W., Isolation and properties of a thrombin-sensitive protein of human platelets Journal of Biological Chemistry 1972 247 9 2723 2731
102. Lawler J. W., Slayter H. S., The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin Thrombosis Research 1981 22 3 267 279
103. Dixit V. M., Grant G. A., Santoro S. A., Frazier W. A., Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin Journal of Biological Chemistry 1984 259 16 10100 10105
104. Gogstad G. O., Solum N. O., Krutnes M. B., Heparin-binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis British Journal of Haematology 1983 53 4 563 573
105. Lahav J., Schwartz M. A., Hynes R. O., Analysis of platelet adhesion with a radioactive chemical crosslinking reagent: interaction of thrombospondin with fibronectin and collagen Cell 1982 31 1 253 262
106. Lahav J., Lawler J., Gimbrone M. A., Thrombospondin interactions with fibronectin and fibrinogen. Mutual inhibition in binding European Journal of Biochemistry 1984 145 1 151 156
107. Leung L. L. K., Nachman R. L., Complex formation of platelet thrombospondin with fibrinogen Journal of Clinical Investigation 1982 70 3 542 549
108. Tuszynski G. P., Srivastava S., Switalska H. I., Holt J. C., Cierniewski C. S., Niewiarowski S., The interaction of human platelet thrombospondin with fibrinogen: thrombospondin purification and specificity of interaction Journal of Biological Chemistry 1985 260 22 12240 12245
109. Silverstein R. L., Leung L. L. K., Harpel P. C., Nachman R. L., Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein Journal of Clinical Investigation 1985 75 6 2065 2073
110. Leung L. L. K., Nachman R. L., Harpel P. C., Complex formation of platelet thrombospondin with histidine-rich glycoprotein Journal of Clinical Investigation 1984 73 1 5 12
111. Mumby S. M., Raugi G. J., Bornstein P., Interactions of thrombospondin with extracellular matrix proteins: selective binding to type V collagen Journal of Cell Biology 1984 98 2 646 652
112. Lawler J., Simons E. R., Cooperative binding of calcium to thrombospondin. The effect of calcium on the circular dichroism and limited tryptic digestion of thrombospondin Journal of Biological Chemistry 1983 258 20 12098 12101
113. Phillips D. R., Jennings L. K., Prasanna H. R., Ca2+mediated association of glycoprotein G (thrombin sensitive protein, thrombospondin) with human platelets Journal of Biological Chemistry 1980 255 24 11629 11632
114. Lahav J., The functions of thrombospondin and its involvement in physiology and pathophysiology Biochimica et Biophysica Acta 1993 1182 1 1 14
115. Raugi G. J., Mumby S. M., Abbott-Brown D., Bornstein P., Thrombospondin: synthesis and secretion by cells in culture Journal of Cell Biology 1982 95 1 351 354
116. Jaffe E. A., Ruggiero J. T., Leung L. L. K., Doyle M. J., McKeown-Longo P. J., Mosher D. F., Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix Proceedings of the National Academy of Sciences of the United States of America 1983 80 4 998 1002
117. McKeown-Longo P. J., Hanning R., Mosher D. F., Binding and degradation of platelet thrombospondin by cultured fibroblasts Journal of Cell Biology 1984 98 1 22 28
118. McPherson J., Sage H., Bornstein P., Isolation and characterization of a glycoprotein secreted by aortic endothelial cells in culture. Apparent identity with platelet thrombospondin Journal of Biological Chemistry 1981 256 21 11330 11336
119. Mosher D. F., Doyle M. J., Jaffe E. A., Synthesis and secretion of thrombospondin by cultured human endothelial cells Journal of Cell Biology 1982 93 2 343 348
120. Lawler J., The structural and functional properties of thrombospondin Blood 1986 67 5 1197 1209
121. Lawler J., Derick L. H., Connolly J. E., Chen J. H., Chao F. C., The structure of human platelet thrombospondin Journal of Biological Chemistry 1985 260 6 3762 3772
122. Lawler J., Slayter H. S., Coligan J. E., Isolation and characterization of a high molecular weight glycoprotein from human blood platelets Journal of Biological Chemistry 1978 253 23 8609 8616
123. Lawler J., Chao F. C., Fang P. H., Observation of a high molecular weight platelet protein released by thrombin Thrombosis and Haemostasis 1977 37 2 355 357
124. Bornstein P., Thrombospondins: structure and regulation of expression FASEB Journal 1992 6 14 3290 3299
125. Coligan J. E., Slayter H. S., Structure of thrombospondin Journal of Biological Chemistry 1984 259 6 3944 3948
126. Lawler J., Hynes R. O., The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins Journal of Cell Biology 1986 103 5 1635 1648
127. Lawler J., Duquette M., Urry L., McHenry K., Smith T. F., The evolution of the thrombospondin gene family Journal of Molecular Evolution 1993 36 6 509 516
128. Adams J. C., Thrombospondins: multifunctional regulators of cell interactions Annual Review of Cell and Developmental Biology 2001 17 25 51
129. Bornstein P., Sage E. H., Thrombospondins Methods in Enzymology 1994 245 62 85
130. Adams J., Lawler J., The thrombospondin family Current Biology 1993 3 3 188 190
131. Taraboletti G., Roberts D., Liotta L. A., Giavazzi R., Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor Journal of Cell Biology 1990 111 2 765 772
132. Majack R. A., Goodman L. V., Dixit V. M., Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation Journal of Cell Biology 1988 106 2 415 422
133. Taraboletti G., Roberts D. D., Liotta L. A., Thrombodspondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains Journal of Cell Biology 1987 105 5 2409 2415
134. Vogel T., Guo N., Krutzsch H. C., Blake D. A., Hartman J., Mendelovitz S., Panet A., Roberts D. D., Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin Journal of Cellular Biochemistry 1993 53 1 74 84
135. Ketis N. V., Lawler J., Hoover R. L., Karnosvky M. J., Effects of heat shock on the expression of thrombospondin by endothelial cells in culture Journal of Cell Biology 1988 106 3 893 904
136. Ketis N. V., Lawler J., Effects of thrombospondin antibody on the recovery of endothelial cells from hyperthermia Journal of Cell Science 1990 96 2 263 270
137. Kreis C., La Fleur M., Menard C., Paquin R., Beaulieu A. D., Thrombospondin and fibronectin are synthesized by neutrophils in human inflammatory joint disease and in a rabbit model of in vivo neutrophil activation Journal of Immunology 1989 143 6 1961 1968
138. Jaffe E. A., Ruggiero J. T., Falcone D. J., Monocytes and macrophages synthesize and secrete thrombospondin Blood 1985 65 1 79 84
139. O'Shea K. S., Liu L.-H. J., Kinnunen L. H., Dixit V. M., Role of the extracellular matrix protein thrombospondin in the early development of the mouse embryo Journal of Cell Biology 1990 111 6 2713 2723
140. Bornstein P., Agah A., Kyriakides T. R., The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury International Journal of Biochemistry and Cell Biology 2004 36 6 1115 1125
141. Ren B., Yee K. O., Lawler J., Khosravi-Far R., Regulation of tumor angiogenesis by thrombospondin-1 Biochimica et Biophysica Acta 2006 1765 2 178 188
142. Chen H., Herndon M. E., Lawler J., The cell biology of thrombospondin-1 Matrix Biology 2000 19 7 597 614
143. Lawler J., Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth Journal of Cellular and Molecular Medicine 2002 6 1 1 12
144. Zabrenetzky V., Harris C. C., Steeg P. S., Roberts D. D., Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma International Journal of Cancer 1994 59 2 191 195
145. Weinstat-Saslow D. L., Zabrenetzky V. S., VanHoutte K., Frazier W. A., Roberts D. D., Steeg P. S., Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis Cancer Research 1994 54 24 6504 6511
146. Sheibani N., Frazier W. A., Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis Proceedings of the National Academy of Sciences of the United States of America 1995 92 15 6788 6792
147. Bleuel K., Popp S., Fusenig N. E., Stanbridge E. J., Boukamp P., Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization Proceedings of the National Academy of Sciences of the United States of America 1999 96 5 2065 2070
148. Hsu S. C., Volpert O. V., Steck P. A., Mikkelsen T., Polverini P. J., Rao S., Chou P., Bouck N. P., Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1 Cancer Research 1996 56 24 5684 5691
149. Streit M., Velasco P., Brown L. F., Skobe M., Richard L., Riccardi L., Lawler J., Detmar M., Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas American Journal of Pathology 1999 155 2 441 452
150. Fontana A., Filleur S., Guglielmi J., Frappart L., Bruno-Bossio G., Boissier S., Cabon F., Clzardin P., Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo International Journal of Cancer 2005 116 5 686 691
151. Grossfeld G. D., Ginsberg D. A., Stein J. P., Bochner B. H., Esrig D., Groshen S., Dunn M., Nichols P. W., Taylor C. R., Skinner D. G., Cote R. J., Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression Journal of the National Cancer Institute 1997 89 3 219 227
152. Alvarez A. A., Axelrod J. R., Whitaker R. S., Isner P. D., Bentley R. C., Dodge R. K., Rodriguez G. C., Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients Gynecologic Oncology 2001 82 2 273 278
153. Yao L., Zhao Y.-L., Itoh S., Wada S., Yue L., Furuta I., Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival Oral Oncology 2000 36 6 539 544
154. Tanaka K., Sonoo H., Kurebayashi J., Nomura T., Ohkubo S., Yamamoto Y., Yamamoto S., Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma Clinical Cancer Research 2002 8 5 1125 1131
155. Kodama J., Hashimoto I., Seki N., Hongo A., Yoshinouchi M., Okuda H.,
156. Kawahara N., Ono M., Taguhi K.-I., Okamoto M., Shimada M., Takenaka K., Hayashi K., Mosher D. F., Sugimachi K., Tsuneyoshi M., Kuwano M., Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma Hepatology 1998 28 6 1512 1517
157. Kodama J., Hashimoto I., Seki N., Hongo A., Yoshinouchi M., Okuda H., Kudo T., Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor Anticancer Research 2001 21 4 2983 2987
158. Folkman J., Anti-angiogenesis: new concept for therapy of solid tumors Annals of Surgery 1972 175 3 409 416
159. Teicher B. A., A systems approach to cancer therapy Cancer and Metastasis Reviews 1996 15 2 247 272
160. Fukumura D., Jain R. K., Imaging angiogenesis and the microenvironment APMIS 2008 116 7-8 695 715
161. Lu C., Kamat A. A., Lin Y. G., Merritt W. M., Landen C. N., Tae J. K., Spannuth W., Arumugam T., Han L. Y., Jennings N. B., Logsdon C., Jaffe R. B., Coleman R. L., Sood A. K., Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma Clinical Cancer Research 2007 13 14 4209 4217
162. Tozer G. M., Kanthou C., Lewis G., Prise V. E., Vojnovic B., Hill S. A., Tumour vascular disrupting agents: combating treatment resistance British Journal of Radiology 2008 81 S12 S20
163. Fukumura D., Jain R. K., Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization Microvascular Research 2007 74 2-3 72 84
164. Jain R. K., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nature Medicine 2001 7 9 987 989
165. Dickson P. V., Hamner J. B., Sims T. L., Fraga C. H., Ng C. Y. C., Rajasekeran S., Hagedorn N. L., McCarville M. B., Stewart C. F., Davidoff A. M., Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clinical Cancer Research 2007 13 13 3942 3950
166. Yap R., Veliceasa D., Emmenegger U., Kerbel R. S., McKay L. M., Henkin J., Volpert O. V., Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy Clinical Cancer Research 2005 11 18 6678 6685
167. Greenaway J., Lawler J., Moorehead R., Bornstein P., Lamarre J., Petrik J., Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1) Journal of Cellular Physiology 2007 210 3 807 818
168. Greenaway J., Henkin J., Lawler J., Moorehead R., Petrik J., ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer Molecular Cancer Therapeutics 2009 8 1 64 74
169. Bein K., Simons M., Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity Journal of Biological Chemistry 2000 275 41 32167 32173
170. Qian X., Rothman V. L., Nicosia R. F., Tuszynski G. P., Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production Pathology and Oncology Research 2001 7 4 251 259
171. Agah A., Kyriakides T. R., Lawler J., Bornstein P., The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice American Journal of Pathology 2002 161 3 831 839
172. Herndon M. E., Stipp C. S., Lander A. D., Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding Glycobiology 1999 9 2 143 155
173. Elzie C. A., Murphy-Ullrich J. E., The N-terminus of thrombospondin: the domain stands apart International Journal of Biochemistry and Cell Biology 2004 36 6 1090 1101
174. Ferrari do Outeiro-Bernstein M. A., Nunes S. S., Andrade A. C. M., Alves T. R., Legrand C., Morandi V., A recombinant NH2-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan Matrix Biology 2002 21 4 311 324
175. Anonick P. K., Yoo J. K., Webb D. J., Gonias S. L., Characterization of the antiplasmin activity of human thrombospondin-1 in solution Biochemical Journal 1993 289 3 903 909
176. Hogg P. J., Thrombospondin 1 as an enzyme inhibitor Thrombosis and Haemostasis 1994 72 6 787 792